Last reviewed · How we verify
NCT07527091
Efficacy of Ultrasound-Guided Percutaneous Electrolysis for Hip Pain in Male Ice Hockey Players
NA trial testing Ultrasound-guided musculoskeletal percutaneous electrolysis in Groin Pain in 6 participants. Completed in 23 March 2026.
23 March 2026
Quick facts
| Lead sponsor | Veronique Vidal |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 2 February 2026 |
| Primary completion | 23 March 2026 |
| Estimated completion | 23 March 2026 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Ultrasound-guided musculoskeletal percutaneous electrolysis
Conditions studied
- Groin Pain — all drugs for Groin Pain →
- Hip Joint Disorders — all drugs for Hip Joint Disorders →
Sponsor
Veronique Vidal
Who can join
Adults 18 to 21, male only, with Groin Pain or Hip Joint Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Groin pain is a common and limiting condition in ice hockey players, often related to the high mechanical demands placed on the hip during skating. Repetitive movements involving hip flexion, abduction, and rotation may contribute to functional impairment and persistent symptoms. Recent clinical interest has focused on the relationship between the iliopsoas muscle and the anterior hip capsule, as their close anatomical and functional interaction may play a role in the development of hip-related groin pain. Percutaneous needle electrolysis (PNE) is a minimally invasive, ultrasound-guided technique used to promote tissue remodeling and pain reduction in musculoskeletal conditions. However, its application to the anterior hip capsule has not yet been investigated. This pilot experimental study aims to evaluate the effects of three sessions of PNE applied to the anterior hip capsule in male ice hockey players with groin pain. The main hypothesis is that this intervention may improve hip function by reducing pain and enhancing mobility and muscle strength. Outcomes include hip flexor strength, hip flexion range of motion, FADIR test results, and patient-reported outcomes measured with the HAGOS questionnaire. Assessments will be performed before and after the intervention, as well as at a 4-week follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07527091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07527091 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Veronique Vidal
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing